Theragnostic Technologies was established in 2012 as a spin-off from Stony Brook University to develop a new efficient graphene-based MRI contrast agent that is safer and cheaper than current gadolinium-based agents.
The company unveiled its product, called ManGraDex, in June 2015. The ManGraDex needs to go through several clinical trial phases, and commercialization is planned for 2022 or 2023. Theragnostic is supported by the NIH Commercialization Accelerator Program.
Contact information for Theragnostic Technologies
8 Windover Lane
Coram, NY 11727
United States
Theragnostic Technologies receives grant to expand its graphene-based contrast agent platform to X-Ray CT procedures
In 2012, researchers from Stony Brook University established Theragnostic Technologies to develop a new efficient and cost-effective graphene-based MRI contrast agent. In 2015 Theragnostic launched the product, called ManGraDex, which needs several of years of clinical trials before it can be commercialized (the company aims for 2022 or 2023).
Theragnostic Technologies now announced that it has received a new SBIR phase-1 grant from the NIH to extend the ManGraDex platform for use in X-ray Computed Tomography (CT) imaging. The company will demonstrate the preclinical safety and efficacy of a novel graphene-enhanced CT contrast agent for imaging and monitoring in patients with renal failure or at risk of contrast induced nephropathy.
Theragnostic Technologies to launch a graphene-based MRI agent next month
In 2012, researchers from Stony Brook University established a new company called Theragnostic Technologies to develop a new efficient graphene-based MRI contrast agent that is safer and cheaper than current gadolinium-based agents.
Next month the company is set to unveil its product, the ManGraDex graphene-based MRI agent. The company says that this new contrast agent will greatly improve the MRI safety and efficacy of MRI - and will also expand the MRI market into unserved renal and cardiovascular patients.
Graphene based MRI contrast agent is safer, cheaper and more efficient than current agents
Researchers from Stony Brook University developed a new efficient graphene-based MRI contrast agent that's potentially safer and cheaper than current gadolinium-based agents. The new agent can also improve disease detection because of its sensitivity and diagnostic confidence.
Dr. Sitharaman, who led the research, has established a new company called Theragnostic Technologies which is set to commercialize this new agent.
